ClinicalTrials.gg
CompletedNCT05413135Updated May 12, 2026

Study of ARO-APOC3 in Adults With Dyslipidemia

A Phase 2 interventional study of ARO-APOC3 in Dyslipidemias, sponsored by Arrowhead Pharmaceuticals. Completed at 60 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Arrowhead Pharmaceuticals · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
418
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 349 studies in Dyslipidemias with a site in United States — 23 open to participants now, 34 under way, 6 of them phase 3. Dyslipidemias · United States.

Enrollment
61st of 316
418 · median 105
Started
2022
with 9 others
Phase 2
66 of 349
2 open now
Registered
291st of 349
by date

Among the 349 studies in Dyslipidemias with a site in United States, this one is the 61st largest by enrollment of the 316 interventional ones that give a count, is one of 10 that started in 2022, is one of 66 in phase 2, and was the 291st registered.

Dyslipidemias

1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

Browse Dyslipidemias studies →

Open to participants now

23 of the 349 studies in Dyslipidemias with a site in United States are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies in Dyslipidemias with a site in United States, or all of them as a file.
02

Study summary

This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded 12-month period from either parent study and continued to meet eligibility criteria had the option to be enrolled into this study. Eligible enrolled participants initially received open-label ARO-APOC3 every three or six months at the assigned dose level of the parent study until a final dose of 25 mg was selected, at which point all participants transitioned to the selected dosing regimen of 25 mg every 3 months.

03

Conditions studied

  • Dyslipidemias

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults who are nonpregnant, nonlactating and do not plan to become pregnant during the study
  • Able and willing to provide written
  • Completed the 48-week study treatment period in the parent study

Exclusion criteria

Exclusion Criteria:

  • Subject was permanently discontinued from ARO-APOC3 in the parent study due to elevated (HbA1c), (AST) or alanine aminotransferase (ALT)
  • Any new condition or worsening of existing condition or any other situation that would make the subject unsuitable for enrollment, could interfere with the subject participating in or completing the study, would make it difficult to comply with protocol requirements or put the subject at additional safety risk
  • Unwilling to limit alcohol consumption to within moderate limits for the duration of the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
418 participants (actual)

Study arms

  • Experimental
    ARO-APOC3

    1 dose of ARO-APOC3 by subcutaneous (sc) injection every 3 months

    Drug: ARO-APOC3

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Through 24 months

Secondary outcomes

  1. Change from Baseline in Fasting Triglycerides (TG) Over Time

    Time frame: Through 24 months

  2. Percent Change from Baseline in Fasting TG Over Time

    Time frame: Through 24 months

  3. Change from Baseline in Apolipoprotein (Apo) C-III Over Time

    Time frame: Through 24 months

  4. Percent Change from Baseline in ApoC-III Over Time

    Time frame: Through 24 months

  5. Change from Baseline in Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) Over Time

    Time frame: Through 24 months

  6. Percent Change from Baseline in Fasting Non-HDL-C Over Time

    Time frame: Through 24 months

  7. Change from Baseline in Fasting High-Density Lipoprotein-Cholesterol (HDL-C) Over Time

    Time frame: Through 24 months

  8. Percent Change from Baseline in Fasting HDL-C Over Time

    Time frame: Through 24 months

  9. Change from Baseline in Fasting Total Apolipoprotein B (ApoB) Over Time

    Time frame: Through 24 months

  10. Percent Change from Baseline in Fasting Total ApoB Over Time

    Time frame: Through 24 months

  11. Change from Baseline in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C) Over Time Using Ultracentrifugation

    Time frame: Through 24 months

  12. Percent Change from Baseline in Fasting LDL-C Over Time Using Ultracentrifugation

    Time frame: Through 24 months

07

Study locations

60 sites
  • Clinical Research Site 1
    Beverly Hills, California 90211, United States
  • Clinical Research Site 2
    Northridge, California 91325, United States
  • Clinical Research Site 3
    Palm Springs, California 92292, United States
  • Clincal Research Site 4
    Boca Raton, Florida 33434, United States
  • Clinical Research Site 5
    Fort Lauderdale, Florida 33308, United States
  • Clinical Research Site 8
    Miami, Florida 33155, United States
  • Clinical Research Site 6
    Miami, Florida 33173, United States
  • Clinical Research Site 9
    Miami Springs, Florida 33166, United States
  • Clinical Research Site 10
    Pembroke Pines, Florida 33024, United States
  • Clinical Research Site 11
    Port Orange, Florida 32127, United States
  • Clinical Research Site 12
    Dunwoody, Georgia 30338, United States
  • Clinical Research Site 13
    Minneapolis, Minnesota 55455, United States
  • Clinical Research Site 14
    Tupelo, Mississippi 38801, United States
  • Clinical Research Site 15
    Omaha, Nebraska 68114, United States
  • Clinical Research Site 16
    Las Vegas, Nevada 89121, United States
  • Clinical Research Site 17
    Long Island City, New York 11106, United States
  • Clinical Research Site 18
    New Windsor, New York 12553, United States
  • Clinical Research Site 19
    New York, New York 10029, United States
  • Clinical Research Site 20
    Morehead City, North Carolina 28557, United States
  • Clinical Research Site 21
    Fargo, North Dakota 58104, United States
  • Clinical Research Site 22
    Marion, Ohio 43302, United States
  • Clinical Research Site 23
    Maumee, Ohio 43537, United States
  • Clinical Research Site 24
    Oklahoma City, Oklahoma 73135, United States
  • Clinical Research Site 25
    Greenville, South Carolina 29607, United States
  • Clinical Research Site 26
    Chattanooga, Tennessee 37421, United States
  • Clinical Research Site 29
    Houston, Texas 77002, United States
  • Clinical Research Site 27
    Houston, Texas 77030, United States
  • Clinical Research Site 28
    Houston, Texas 77099, United States
  • Clinical Research Site 30
    San Antonio, Texas 78249, United States
  • Clinical Research Site 31
    Manassas, Virginia 20110, United States
  • Clinical Research Site 32
    Camperdown, New South Wales 2050, Australia
  • Clinical Research Site 33
    Milton, Queensland 4068, Australia
  • Clinical Research Site 34
    Sippy Downs, Queensland 4556, Australia
  • Clinical Research Site 35
    Adelaide, South Australia 5000, Australia
  • Clinical Research Site 36
    Clayton, Victoria 3168, Australia
  • Clinical Research Site 37
    Joondalup, Washington 6027, Australia
  • Clinical Research Site 38
    Nedlands, Washington 6009, Australia
  • Clinical Research Site 39
    Concord, Ontario L4K4M2, Canada
  • Clinical Research Site 40
    London, Ontario N6A 5A5, Canada
  • Clinical Research Site 41
    Chicoutimi, Quebec G7H 7K9, Canada
  • Clinical Research Site 43
    Montreal, Quebec H2W 1R7, Canada
  • Clinical Research Site 44
    Québec, Quebec G1G 3Z4, Canada
  • Clinical Research Site 46
    Balatonfüred, H-8230, Hungary
  • Clinical Research Site 47
    Békéscsaba, 5600, Hungary
  • Clinical Research Site 48
    Debrecen, 4032, Hungary
  • Clinical Research Site 49
    Gyöngyös, 3200, Hungary
  • Clinical Research Site 50
    Komárom, H-2900, Hungary
  • Clinical Research Site 51
    Nyíregyháza, 4400, Hungary
  • Clinical Research Site 53
    Amsterdam, 1105 AZ, Netherlands
  • Clinical Research Site 54
    Sneek, 8601 ZR, Netherlands
  • Clinical Research Site 55
    Zwijndrecht, 3331LZ, Netherlands
  • Clinical Research Site 58
    Papatoetoe, Aukland 2025, New Zealand
  • Clinical Research Site 56
    Christchurch, 8011, New Zealand
  • Clinical Research Site 57
    Christchurch, 8013, New Zealand
  • Clinical Research Site 59
    Bydgoszcz, 85-605, Poland
  • Clinical Research Site 64
    Lodz, 93-338, Poland
  • Clinical Research Site 63
    Lodz, 94 046, Poland
  • Clinical Research Site 60
    Oświęcim, 32-600, Poland
  • Clinical Research Site 61
    Poznan, 61-655, Poland
  • Clinical Research Site 62
    Rzeszów, 35-055, Poland
08

References and documents

Publications

  • Ballantyne CM, Baass A, Rosenson RS, Hegele RA, Nicholls SJ, Vasas S, Clifton P, Lucas KJ, Pall D, Zhou R, Leeper NJ, Hellawell J, Aiyer L, Watts GF, Gaudet D. Use of plozasiran across a spectrum of hypertriglyceridemia: Long-term efficacy and safety data from the open-label extension period of SHASTA-2 and MUIR Trials. Am J Prev Cardiol. 2026 Mar 24;27:101523. doi: 10.1016/j.ajpc.2026.101523. eCollection 2026 Jun. PubMed 42291067 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Sep 2025, 38 months.

Of 35 industry-sponsored phase 2 interventional studies under Dyslipidemias, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 38 months is above that.

Counting every sponsor, half of 43 studies reached it within 13 months; a quarter within 7 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2022
First posted
Jun 9, 2022
StartActual
Jul 7, 2022
Primary completionActual
Sep 22, 2025
CompletionActual
Sep 22, 2025
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05413135
Responsible party
Sponsor
First posted
Jun 9, 2022
Start date
Jul 7, 2022
Primary completion
Sep 22, 2025
Completion
Sep 22, 2025
Last update
May 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plozasiran

Start the discussion